NCT01602510 - Lamotrigine Phase III Study in Bipolar I Disorder | Biotech Hunter

Enrollment

265

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions

Bipolar Disorder

Interventions

DRUG

Lamotrigine

in the double blind phase, lamotrigine 200mg/day will be used among half of eligible subjects after randomization

DRUG

Placebo

Trial Locations (21)

100083

GSK Investigational Site, Beijing

100088

GSK Investigational Site, Beijing

100096

GSK Investigational Site, Beijing

150070

GSK Investigational Site, Harbin

200030

GSK Investigational Site, Shanghai

210029

GSK Investigational Site, Nanjing

310003

GSK Investigational Site, Hangzhou

310009

GSK Investigational Site, Hangzhou

410011

GSK Investigational Site, Changshacun

430022

GSK Investigational Site, Wuhan

510180

GSK Investigational Site, Guangzhou

510370

GSK Investigational Site, Guangzhou

510630

GSK Investigational Site, Guangzhou

610041

GSK Investigational Site, Chengdu

650032

GSK Investigational Site, Kunming

710032

GSK Investigational Site, Xi'an

071000

GSK Investigational Site, Baoding

050000

GSK Investigational Site, Shijiazhuang

Unknown

GSK Investigational Site, Xinxiang

GSK Investigational Site, Changsha

GSK Investigational Site, Taiyuan